about
Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markersGenetic regulation of warfarin metabolism and responseHLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin.Drug-induced liver injury: recent advances in diagnosis and risk assessment.Dynamics of 5-carboxylcytosine during hepatic differentiation: Potential general role for active demethylation by DNA repair in lineage specification.Mass spectrometric characterization of circulating covalent protein adducts derived from a drug acyl glucuronide metabolite: multiple albumin adductions in diclofenac patients.Causality assessment for suspected DILI during clinical phases of drug developmentSafety and long term efficacy of porfimer sodium photodynamic therapy in locally advanced biliary tract carcinoma.Monitoring liver function during methotrexate therapy for psoriasis: are routine biopsies really necessary?The communication of a secondary care diagnosis of autoimmune hepatitis to primary care practitioners: a population-based study.TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease.Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles.Direct targeting of risk factors significantly increases the detection of liver cirrhosis in primary care: a cross-sectional diagnostic study utilising transient elastography.Autoimmune cholestatic liver disease in people with coeliac disease: a population-based study of their association.Squamous cell carcinoma of the pancreas: report of a case and review of the literature.Biomarkers in liver disease: emerging methods and potential applicationsBrunner's gland hyperplasia at the ampulla of Vater.Elevated serum alanine transaminase in patients with type 1 or type 2 diabetes mellitus.Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs.Nonsteroidal anti-inflammatory drug-induced hepatotoxicity.The antecedents of biliary cancer: a primary care case-control study in the United Kingdom.Immune dysfunction in patients with obstructive jaundice before and after endoscopic retrograde cholangiopancreatography.Non-invasive assessment of portal hypertension using quantitative magnetic resonance imaging.Hepatotoxicity Related to Anti-tuberculosis Drugs: Mechanisms and Management.Hepatotoxicity related to antirheumatic drugs.Case definition and phenotype standardization in drug-induced liver injury.The phenotype standardization project: improving pharmacogenetic studies of serious adverse drug reactions.Genetic basis of drug-induced liver injury: present and future.Human leukocyte antigen genetic risk factors of drug-induced liver toxicology.Pharmacogenetic testing in idiosyncratic drug-induced liver injury: current role in clinical practice.Genome-Wide Association Studies in Drug-Induced Liver Injury: Step Change in Understanding the Pathogenesis.Economic evaluation of a community-based diagnostic pathway to stratify adults for non-alcoholic fatty liver disease: a Markov model informed by a feasibility study.HLA-DRB1*16: 01-DQB1*05: 02 is a novel genetic risk factor for flupirtine-induced liver injury.Clinical and microbiological features of infection in alcoholic hepatitis: an international cohort study.Effects of short-term energy restriction on liver lipid content and inflammatory status in severely obese adults: Results of a randomized controlled trial using 2 dietary approaches.Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study.A Randomized, Placebo-Controlled Trial of Cenicriviroc for Treatment of Nonalcoholic Steatohepatitis with Fibrosis.Risk of hepatocellular carcinoma among individuals with different aetiologies of cirrhosis: a population-based cohort study.Minocycline hepatotoxicity: Clinical characterization and identification of HLA-B∗35:02 as a risk factor.A study of T₁ relaxation time as a measure of liver fibrosis and the influence of confounding histological factors.
P50
Q28258678-34DB7FE1-0309-411D-B311-4FA487A31D02Q28267140-F9372A4D-D3E2-4A48-AA58-9F10A3871AC1Q29417159-F3D64E2E-35C9-4FB6-B45F-F9BC76EFF2E4Q30235089-5DD544F4-1ACE-42D7-B0F1-C06C4BADF1A1Q33585534-98C44E3F-ED0D-4483-9022-8F245C7C1E63Q33944025-3B3FF835-A704-44CB-A93E-F816E43C2E12Q34417032-DEB64225-F721-49F1-B647-6D1DF7E32890Q34496924-C5DFB853-055E-4194-A188-C42794172478Q34563288-CBA569F1-6AEE-4AAE-AA4C-CB97FFF40B78Q34698958-866114B1-0221-4ADA-8761-8584A22EEC4CQ34785862-C857BBBB-E7F6-4047-8E1C-F6AE9D5B2966Q35085772-7E7FA2B3-E1F9-44D7-BB67-70F0E6106D39Q35573240-22D5D8C4-BC74-4BDA-A13B-843A59F647ABQ36041175-C342C9D7-AC79-46D1-9DEF-70A2EFFAEE7FQ36366269-7FC863F4-2438-4AD9-BFD6-37B87C0B6F5EQ36413685-32A2B5D1-D638-4FD1-9A38-3C553D4F75A7Q36420184-82A72DB5-B1FB-4E9D-9DD4-CA580DEA728FQ36661233-9E8062D0-FF81-4AFA-B4F1-870F029864C1Q36796350-F00BF090-5D32-47BD-B146-C6B0160C129DQ36920992-221F2C21-1ABF-4088-9C68-68AC0544FB9FQ37080976-EBD2242B-36BE-4108-8589-FE538AF5898EQ37101358-8B5F781C-934A-4920-9780-36EBB077E09DQ37441985-037E3DC3-82FC-4E3E-B725-611769F3D05BQ37613267-72FF0D31-2181-4DB6-ABB6-9B6E430DE687Q37832129-BE5671EF-778F-4863-B1AA-E9C9B36DE45CQ37872195-E5292548-D7DE-47ED-9CA8-BC22CB58E312Q37877127-C5DB5E3B-0FFD-48AE-9490-A2B8BC33A6A9Q38216267-44538AA4-DB68-4701-A8A6-9DEF61417444Q38285818-FF7E0426-D256-4DED-B83E-8CCABABB44E1Q38391340-E7E07703-D0CE-443B-B440-247E246A2161Q38671650-5756BB77-00A5-4742-84EC-4C0CF0B4644CQ38692351-076994C3-7C0A-4408-A341-A42D48F63B75Q38767081-221E1039-87B4-4C1B-B6BB-5BA07DC4484FQ38847072-0E274505-6FDF-4D4F-B5FC-F649E5558B5EQ38946501-5C658296-A2AC-41F9-8CDC-F37D64926A24Q39043874-267E5E2F-0336-4362-B9CC-421651E32C74Q40082820-5541861E-D060-4B3B-AD19-F9CB4AEADA2DQ40356341-C9F2BBEA-45DE-492B-9B90-32D1B402190EQ40454552-63508E66-6246-4968-B0B9-64E5FA60821BQ41020416-F568B3D3-808D-4FB2-BF85-EF0038774DBC
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Guruprasad P Aithal
@ast
Guruprasad P Aithal
@es
Guruprasad P Aithal
@nl
Guruprasad P Aithal
@sl
Guruprasad P. Aithal
@en
type
label
Guruprasad P Aithal
@ast
Guruprasad P Aithal
@es
Guruprasad P Aithal
@nl
Guruprasad P Aithal
@sl
Guruprasad P. Aithal
@en
altLabel
Guruprasad Aithal
@en
Guruprasad P Aithal
@en
prefLabel
Guruprasad P Aithal
@ast
Guruprasad P Aithal
@es
Guruprasad P Aithal
@nl
Guruprasad P Aithal
@sl
Guruprasad P. Aithal
@en
P108
P106
P108
P31
P496
0000-0003-3924-4830